You just read:

Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets

News provided by

Neurocrine Biosciences, Inc.

Mar 31, 2015, 10:00 ET